ReviewProbiotics and antimicrobial proteins2025
Antimicrobial Peptides: Mechanism, Expressions, and Optimization Strategies.
Review in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Development and Biological Evaluation of FL18-Based Novel Antimicrobial Peptide Constructs Against Bacterial Pathogens.ACS omega · 2026Article
- Phospholipid-Coated FeAntibiotics (Basel, Switzerland) · 2026Article
- Peptidomic Characterization of < 3 kDa Peptides from Milk Fermented by Lactic Acid Bacteria: Sequence-Based Antimicrobial Prediction and In Vitro Immuno-Oncological Evaluation.Probiotics and antimicrobial proteins · 2026Article
- The Snakin Family of Antimicrobial Peptides: Promising Alternatives to Conventional Antibiotics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Promising Future of Engineered Probiotics for Antimicrobial Peptides and Protein Production: Prospects and Industrial Challenges.Probiotics and antimicrobial proteins · 2026Review
- Redefining Therapies for Drug-Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design.Advanced healthcare materials · 2026Review
- Marine-Inspired Antimicrobial Peptides Disrupt Gene Expression at the DNA Level.ACS infectious diseases · 2026Article
- Antimicrobial peptides for anticancer and antiviral therapy: last promising update.Discover oncology · 2025Review
- Current State and Advances in Antimicrobial Strategies for Burn Wound Dressings: From Metal-Based Antimicrobials and Natural Bioactive Agents to Future Perspectives.International journal of molecular sciences · 2025Review
- Antimicrobial Peptides: The Game-Changer in the Epic Battle Against Multidrug-Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) are favoured because of their broad-spectrum antimicrobial properties and because they do not easily develop microbial resistance. However, the low yield and difficult extraction processes of AMPs have become bottlenecks in large-scale industrial applications and scientific research. Microbial recombinant production may be the most economical and effective method of obtaining AMPs in large quantities. In this paper, we review the mechanism, summarize the current status of microbial recombinant production, and focus on strategies to improve the yield and activity of AMPs, in order to provide a reference for their large-scale production.
Indexed as
Identifiers
39528853What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.